Equities Research Analysts’ updated eps estimates for Monday, December 4th:

Aetna (NYSE:AET) had its outperform rating reissued by analysts at Wells Fargo & Company. Wells Fargo & Company currently has a $208.00 target price on the stock, up from their previous target price of $200.00.

American Public Education (NASDAQ:APEI) had its hold rating reaffirmed by analysts at Piper Jaffray Companies. The firm currently has a $29.00 price target on the stock.

DeVry Education Group (NYSE:ATGE) had its buy rating reissued by analysts at Piper Jaffray Companies. The firm currently has a $59.00 target price on the stock.

Callidus Software (NASDAQ:CALD) had its buy rating reaffirmed by analysts at Piper Jaffray Companies.

CVS Health (NYSE:CVS) had its buy rating reaffirmed by analysts at Leerink Swann.

CVS Health (NYSE:CVS) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $85.00 target price on the stock, up from their previous target price of $79.00.

Dollar General (NYSE:DG) had its buy rating reissued by analysts at UBS AG. They currently have a $99.00 price target on the stock, up from their previous price target of $85.00.

Global Blood Therapeutics (NASDAQ:GBT) had its outperform rating reissued by analysts at Wedbush. Wedbush currently has a $73.00 price target on the stock.

Irhythm Technologies (NASDAQ:IRTC) had its outperform rating reiterated by analysts at Royal Bank Of Canada. They currently have a $53.35 target price on the stock.

Illinois Tool Works (NYSE:ITW) had its outperform rating reaffirmed by analysts at Wells Fargo & Company. The firm currently has a $190.00 price target on the stock, up from their previous price target of $170.00.

RhythmOne (LON:RTHM) had its buy rating reissued by analysts at N+1 Singer.

United Natural Foods (NASDAQ:UNFI) had its underperform rating reissued by analysts at Royal Bank Of Canada. The firm currently has a $34.00 target price on the stock.

Wingstop (NASDAQ:WING) had its buy rating reiterated by analysts at Robert W. Baird. They currently have a $44.00 target price on the stock.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) had its positive rating reiterated by analysts at Canaccord Genuity. They currently have a $18.00 target price on the stock, up from their previous target price of $15.00.

Receive News & Ratings for Aetna Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna Inc and related companies with MarketBeat.com's FREE daily email newsletter.